Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


A recent study, published in the journal Neurology assessed foetal risk after pregnancy exposure to natalizumab (Tysabri) in women with multiple sclerosis (MS). The Italian study specifically...

NHS Scotland has accepted cladribine (Mavenclad) as a treatment option for people with highly active multiple sclerosis (MS) living in Scotland.

The Scottish Medicines Consortium (SMC),...

Sandoz, a Novartis division, has announced US Food and Drug Administration (FDA) approval and launched a 40 mg/ml dose of Glatopa, a glatiramer acetate injection.

Glatopa 40 mg/ml is FDA-...

When the body attacks its own healthy tissues in an autoimmune condition, peripheral nerve damage disable people and causes persistent neuropathic pain when insulation on healing nerves doesn't...

A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS...

Of 1,000 women diagnosed with relapsing remitting multiple sclerosis (RRMS) in the last five years, 88% were concerned they would not be able to have children, despite studies that show otherwise...

Biopharmaceutical Company MediciNova has announced additional positive clinical data from its SPRINT-MS phase IIB trial of MN-166 (ibudilast) in progressive multiple sclerosis (PMS).

MN-166...

According to a study, published in the 31 January 2018 online edition of Neurology, the medical journal of the American Academy of Neurology, a special programme of balance and eye movement...

The Dutch Medicines Evaluation Board has signed off AXIM Biotechnologies’ MedChew Rx clinical development programme, which will see them develop and trial a cannabis based chewing gum.

The...

It is difficult to identify patients at risk of disease reactivation. So in a recent study scientists at Cerrahpasa School of Medicine, Istanbul University in Turkey compared the demographic and...

Pages

Live Chat Software by Click4Assistance UK